CIVILICA We Respect the Science
Publisher of Iranian Journals and Conference Proceedings
Paper
title

Circulating Cell-Free Nucleic Acids as Potential Biomarkers for Sarcopenia: A step toward personalized medicine

Credit to Download: 0 | Page Numbers 2 | Abstract Views: 95
Year: 2016
COI code: IPMCMED01_082
Paper Language: English

How to Download This Paper

For Downloading the Fulltext of CIVILICA papers please visit the orginal Persian Section of website.

Authors Circulating Cell-Free Nucleic Acids as Potential Biomarkers for Sarcopenia: A step toward personalized medicine

  Gita Shafiee - Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  Ramin Heshmat - Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  Bagher Larijani - Endocrinology & Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Abstract:

Sarcopenia,a multifactorial geriatric syndrome, is characterized by age-related decline in muscle mass and function. There are multiple intrinsic (biological changes, inflammatory states; etc.) and extrinsic (decreased activity, malnutrition; etc.) factors that participate in the development of sarcopenia . Given the relatively high prevalence and related-outcome of the disease, correct diagnosis, screening, monitoring and treatment of sarcopenia are needed in clinical practice as well as for the conductance of beneficial interventions. In this regard, the global quantitative data from both genetic, biomarkers and body composition could provide a standardized and international comparable readout for successful care. Although, several biological markers have been found to be associated with age-related skeletal muscle decline, but they are not specific to muscle mass and function.Therefore, a good biomarker for sarcopenia must be specifically for muscle changes, accessible, reliable, non-invasive and cost effective. The biomarker could show specific biological processes of sarcopenia to understand specific therapy as a step toward personalized medicine. Recent advances in technologies provide an extraordinary capacity to characterize the genetic alterations and pathways in diseases comprehensively and make it possible to develop therapies, prevention and screening based on the genetic makeup of each disease.Circulating cell- free nucleic acids (ccfNA) in various body fluids have been explored as a novel biomarker in a variety of clinical conditions. The first studies concerning the detection of circulating cell free DNA (cf-DNA)was found in various cancers, metastasis and recurrence of tumor. Both apoptosis and necrosis are as the source of the cf-DNA and so, elevated cf-DNA levels have been observed in other conditions such as cardiovascular diseases, sepsis, and trauma. In the recent years, much attention and effort have been put into studies of other circulating nucleic acids, including circulating RNA, microRNA, mitochondrial DNA, mitochondria RNA than cf-DNA. In addition to assessing the quantities of circulating cf-DNA, qualitative features, such as the cf-DNA methylation level, mutations and fragment size have been offered to be useful diagnostic and prognostic markers in various diseases. Given that sarcopenia is accompanied with increased inflammation, apoptosis and necrosis mediate skeletal muscle fiber loss in age-related mitochondrial enzymatic abnormalities; it represents an amenable condition for which to assess cell free nucleic acids as a candidate biomarker. In conclusion, with development and advances in molecular genetic technology, now is the exact time to focus on ccfNA as a biomarker to access the best therapeutic policy of sarcopenia in personalized medicine and also, to distinguish early stage of sarcopenia without loss of physical or functional independence that might represent a valuable opportunity to carry out interventions to reduce the progress of sarcopenia and prevent physical disability.

Keywords:

Sarcopenia, Circulating Cell-Free Nucleic Acids , Biomarkers

Perma Link

https://www.civilica.com/Paper-IPMCMED01-IPMCMED01_082.html
COI code: IPMCMED01_082

how to cite to this paper:

If you want to refer to this article in your research, you can easily use the following in the resources and references section:
Shafiee, Gita; Ramin Heshmat & Bagher Larijani, 2016, Circulating Cell-Free Nucleic Acids as Potential Biomarkers for Sarcopenia: A step toward personalized medicine, First Personal Medical Congress, تهران, دانشگاه علوم پزشكي ايران - پژوهشكده ملي مهندسي ژنتيك و زيست فناوري ايران، مركز همكاري هاي فناوري و نوآوري هاي رياست جمهوري, https://www.civilica.com/Paper-IPMCMED01-IPMCMED01_082.htmlInside the text, wherever referred to or an achievement of this article is mentioned, after mentioning the article, inside the parental, the following specifications are written.
First Time: (Shafiee, Gita; Ramin Heshmat & Bagher Larijani, 2016)
Second and more: (Shafiee; Heshmat & Larijani, 2016)
For a complete overview of how to citation please review the following CIVILICA Guide (Citation)

Scientometrics

The University/Research Center Information:
Type: Medical University
Paper No.: 6348
in University Ranking and Scientometrics the Iranian universities and research centers are evaluated based on scientific papers.

Research Info Management

Export Citation info of this paper to research management softwares

New Related Papers

Iran Scientific Advertisment Netword

Share this paper

WHAT IS COI?

COI is a national code dedicated to all Iranian Conference and Journal Papers. the COI of each paper can be verified online.